EA202191345A1 - Стабильный состав глюкокортикоидов - Google Patents

Стабильный состав глюкокортикоидов

Info

Publication number
EA202191345A1
EA202191345A1 EA202191345A EA202191345A EA202191345A1 EA 202191345 A1 EA202191345 A1 EA 202191345A1 EA 202191345 A EA202191345 A EA 202191345A EA 202191345 A EA202191345 A EA 202191345A EA 202191345 A1 EA202191345 A1 EA 202191345A1
Authority
EA
Eurasian Patent Office
Prior art keywords
glucocorticoids
stable composition
glucocorticoid
preservatives
relates
Prior art date
Application number
EA202191345A
Other languages
English (en)
Inventor
Тереза Деишер
Адальберт Джарзина
Айэн Данкэн
Original Assignee
Авм Байотекнолоджи, Ллс
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Авм Байотекнолоджи, Ллс filed Critical Авм Байотекнолоджи, Ллс
Publication of EA202191345A1 publication Critical patent/EA202191345A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Изобретение относится к водным фармацевтическим составам, содержащим глюкокортикоид. В их состав входят высокие концентрации глюкокортикоида и сниженные уровни консервантов.
EA202191345A 2018-11-14 2019-11-14 Стабильный состав глюкокортикоидов EA202191345A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862767448P 2018-11-14 2018-11-14
PCT/US2019/061363 WO2020102474A1 (en) 2018-11-14 2019-11-14 Stable glucocorticoid formulation

Publications (1)

Publication Number Publication Date
EA202191345A1 true EA202191345A1 (ru) 2021-10-08

Family

ID=68808595

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202191345A EA202191345A1 (ru) 2018-11-14 2019-11-14 Стабильный состав глюкокортикоидов

Country Status (13)

Country Link
US (1) US20200289650A1 (ru)
EP (1) EP3706721A1 (ru)
JP (2) JP7337060B2 (ru)
KR (2) KR102444113B1 (ru)
CN (1) CN111918645A (ru)
AU (1) AU2019378874A1 (ru)
BR (1) BR112021009365A2 (ru)
CA (1) CA3118505A1 (ru)
EA (1) EA202191345A1 (ru)
IL (1) IL283199A (ru)
MX (1) MX2021005665A (ru)
SG (1) SG11202104702VA (ru)
WO (1) WO2020102474A1 (ru)

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6136607A (en) 1995-11-02 2000-10-24 Bayer Corporation Multi-analyte reference solutions with stable pO2 in zero headspace containers
US20040197333A1 (en) * 2000-02-10 2004-10-07 Cornell Research Foundation, Inc. Use of TGF-beta antagonists to inhibit tumor cell formation or progression
US9694103B2 (en) * 2003-04-16 2017-07-04 The Children's Hospital Of Philadelphia Photochemical activation of surfaces for attaching biomaterial
US20050244472A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Intraocular drug delivery systems containing excipients with reduced toxicity and related methods
US20080038316A1 (en) * 2004-10-01 2008-02-14 Wong Vernon G Conveniently implantable sustained release drug compositions
JP4598484B2 (ja) 2004-11-11 2010-12-15 テルモ株式会社 塩酸リトドリン注射液製剤
WO2007072923A1 (ja) * 2005-12-22 2007-06-28 Kowa Company, Ltd. ステロイドの経時的安定性が改善された外用製剤
AU2013200089B2 (en) * 2006-02-09 2016-03-03 Santen Pharmaceutical Co., Ltd Stable formulations, and methods of their preparation and use
AU2009210741A1 (en) 2008-02-07 2009-08-13 Amgen Inc. Stabilized protein compositions
CN101623291B (zh) 2008-07-07 2011-12-07 天津金耀集团有限公司 一种地塞米松磷酸钠注射液
EP2365812A4 (en) * 2008-11-10 2012-05-16 Nitric Biotherapeutics Inc PHARMACEUTICAL FORMULATIONS FOR THE IONTOPHORETIC DELIVERY OF A CORTICOSTEROID
JP2011136973A (ja) 2009-12-28 2011-07-14 Keiki Imoto 安定なエダラボン含有水性製剤
GB2477545B (en) * 2010-02-05 2011-12-21 Special Products Ltd A liquid morphine composition for buccal administration
EP3530274A1 (en) 2010-08-18 2019-08-28 Theresa Deisher Dexamethasone to reduce stem cell accumulation in the spleen
ITMI20122002A1 (it) 2012-11-26 2014-05-27 Farmacologico Milanese Srl Lab Preparazioni farmaceutiche liquide stabilizzate
JP6741286B2 (ja) 2013-03-28 2020-08-19 テルモ株式会社 包装されたアセトアミノフェン注射液製剤の製造方法
KR101485243B1 (ko) 2013-05-08 2015-01-21 씨제이헬스케어 주식회사 안정화된 페메트렉시드 제제
GR1008921B (el) 2015-12-10 2017-01-12 Φαρματεν Ανωνυμος Βιομηχανικη Και Εμπορικη Εταιρεια Φαρμακευτικων Ιατρικων Και Καλλυντικων Προϊοντων Φαρμακευτικο σκευασμα ελευθερο συντηρητικου για οφθαλμικη χορηγηση περιεχον δεξαμεθαζονη
AU2018243753A1 (en) * 2017-04-01 2019-10-10 Avm Biotechnology, Llc Replacement of cytotoxic preconditioning before cellular immunotherapy
CN107375200A (zh) 2017-06-16 2017-11-24 北京立时达药业有限公司 一种地塞米松磷酸钠注射液及其制备方法
EP3488851A1 (en) * 2018-10-03 2019-05-29 AVM Biotechnology, LLC Immunoablative therapies

Also Published As

Publication number Publication date
WO2020102474A1 (en) 2020-05-22
SG11202104702VA (en) 2021-06-29
KR20220130253A (ko) 2022-09-26
KR102444113B1 (ko) 2022-09-19
JP2021514934A (ja) 2021-06-17
IL283199A (en) 2021-06-30
US20200289650A1 (en) 2020-09-17
CN111918645A (zh) 2020-11-10
KR20200111675A (ko) 2020-09-29
MX2021005665A (es) 2021-09-23
BR112021009365A2 (pt) 2021-08-10
AU2019378874A1 (en) 2021-06-17
JP2023116498A (ja) 2023-08-22
CA3118505A1 (en) 2020-05-22
JP7337060B2 (ja) 2023-09-01
EP3706721A1 (en) 2020-09-16

Similar Documents

Publication Publication Date Title
MX2019015744A (es) Composiciones farmaceuticas.
EA201991799A1 (ru) Диспергируемые в воде составы
EA201991798A1 (ru) Стабильные при хранении составы
MX2020007945A (es) Proteinas f del rsv estabilizadas y usos de las mismas.
MX2022001146A (es) Formulaciones de anticuerpos anti-pvrig y sus usos.
EA202090448A1 (ru) Дигидрооксадиазиноны
EA201892500A1 (ru) Применение фракции лигнина в качестве антифитопатогенного агента и содержащие ее антифитопатогенные композиции
SA521421715B1 (ar) تركيبات سيماجلوتيد ثابتة واستخداماتها
BR112022012410A2 (pt) Degradadores smarca e usos dos mesmos
EA202090732A1 (ru) Составы для трансдермального введения
EA201992509A1 (ru) Гетероарилфениламинохинолины и аналоги
EA201890906A1 (ru) ПРОИЗВОДНЫЕ ХИНОКСАЛИНА И ПИРИДОПИРАЗИНА В КАЧЕСТВЕ ИНГИБИТОРОВ PI3Kβ
EA201891905A1 (ru) Стабильная жидкая композиция гонадотропина
CL2023000491A1 (es) Composiciones de erenumab y usos de las mismas (divisional de solicitud n° 02519-2020).
MX2021014310A (es) Formulaciones de terlipressina.
MX2019009759A (es) Composiciones de peptido estables.
EA202191515A1 (ru) Фармацевтическая композиция, содержащая апиксабан
EA202091471A1 (ru) Полиморфы
EA201892376A1 (ru) Комбинированный состав трех противовирусных соединений
EA202190217A1 (ru) Формы ивосидениба и фармацевтические композиции
EA202191345A1 (ru) Стабильный состав глюкокортикоидов
EA202090788A1 (ru) Жидкая композиция для использования в качестве противовоспалительного средства
EA202191378A1 (ru) Активные сложноэфирные производные тестостерона, их композиции и применения
MX2020010159A (es) Composiciones de creatina y/o creatinina y metodos relacionados.
EA202090971A1 (ru) Способы применения и композиции, содержащие дулаглутид